Market Signal Briefing

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2026, which ended August 31, 2025.

Fiscal Year 2026 First Quarter Highlights

Quarter Ended

August 31, 2025

Pro Forma* YoY Growth

Net Sales

$75.7 million

12.2%

Med Tech Net Sales

$35.3 million

26.1%

Med Device Net Sales

$40.4 million

2.3%

GAAP gross margin of 55.3%

GAAP loss per share of $0.26

Adjusted loss per share of $0.10

Adjusted EBITDA of $2.2 million

Ended fiscal 2026 first quarter with $38.8 million in cash and cash equivalents, ahead of expectations, continues to expect to be cash flow positive for the full year FY 2026

First patients enrolled in both the AMBITION BTK and RECOVER-AV trials

NanoKnife PRESERVE study published in the journal of European Urology

*Pro forma results exclude the Dialysis and BioSentry businesses divested in June 2023 and the PICC, Midline and tip location product portfolios divested in February 2024, as well as the discontinued Radiofrequency and Syntrax support catheter products in February 2024.

“We had an outstanding first quarter as we continued to build off of the strong momentum created in fiscal 2025,” commented Jim Clemmer, President and Chief Executive Officer of AngioDynamics, Inc. “Our strategy to bring unique platform technologies to large, fast growing global markets has paid off as we reported our fourth quarter in a row of MedTech growth of over 20%. This continued performance, combined with our disciplined focus on operational excellence, is driving sustained profitable growth.”

Mr. Clemmer continued, “Our exceptional team is executing our vision to deliver transformative technologies that expand treatment options and help patients live healthier, happier lives. With our superior technologies supported by our clinical investments and the strength of our balance sheet, we remain well-positioned to drive consistent, profitable growth, and deliver sustained value creation during the balance of 2026 and beyond.”

Fiscal Year 2026 First Quarter Financial Results

Unless otherwise noted, all financial comparisons below are presented on a pro forma basis excluding the Dialysis and BioSentry businesses divested in June 2023, the PICC, Midline, and tip location product portfolios divested in February 2024, and the RadioFrequency and Syntrax support catheter products discontinued in February 2024.

Net sales for the first quarter of fiscal year 2026 were $75.7 million, an increase of 12.2% compared to the prior-year quarter.

Med Tech net sales were $35.3 million, a 26.1% increase from $28.0 million in the prior-year period. Med Tech includes the Auryon peripheral atherectomy platform, the thrombus management platform and the NanoKnife irreversible electroporation platform.

Growth during the quarter was driven by solid performance across the Med Tech segment. Auryon sales were $16.5 million an increase of 20.1%, our Mechanical Thrombectomy business, which includes AngioVac and AlphaVac, delivered sales of $11.3 million, an increase of 41.2%, and NanoKnife sales were $6.4 million, an increase of 26.7%, including 31.3% growth in probes.

Med Device net sales were $40.4 million, a 2.3% increase compared to $39.5 million in the prior-year period.

Gross margin for the first quarter of fiscal 2026 was 55.3%, which was 90 basis points higher compared to the first quarter of fiscal 2025, and 260 basis points higher sequentially from 52.7% in the fourth quarter of fiscal 2025, primarily due to increased Med Tech revenue, as well as operational efficiencies. Gross margin included $1.7 million of tariff expense.

The Company recorded a GAAP net loss of $10.9 million, or a loss per share of $0.26, in the first quarter of fiscal 2026. Excluding the items shown in the non-GAAP reconciliation table below, adjusted net loss for the first quarter of fiscal 2026 was $4.2 million, or a loss per share of $0.10. This compares to an adjusted net loss during the fiscal first quarter of 2025 of $4.4 million, or a loss per share of $0.11.

Adjusted EBITDA in the first quarter of fiscal 2026, excluding the items shown in the non-GAAP reconciliation table below, was $2.2 million, compared to $(0.2) million in the first quarter of fiscal 2025.

In the first quarter of fiscal 2026, the Company used $17.1 million of cash. The Company’s first fiscal quarter has historically exhibited the highest utilization of cash during the year, and the first quarter of fiscal 2026 was better than the Company’s expectations, resulting in the use of less cash than expected. The Company continues to expect to be cash flow positive for the full year fiscal 2026.

At August 31, 2025, the Company had $38.8 million in cash and cash equivalents compared to $55.9 million in cash and cash equivalents at May 31, 2025. The Company maintains a debt-free balance sheet.

First Patient Enrolled in AMBITION BTK Trial

During the quarter, the Company announced that it achieved a significant clinical milestone with the enrollment of the first patient in the AMBITION BTK trial, a prospective, multicenter, randomized controlled trial designed to investigate the clinical safety and effectiveness of the Auryon Atherectomy System in treating challenging below-the-knee lesions in patients with Critical Limb Ischemia. The trial will include up to 224 patients at up to 30 sites, with a companion registry enrolling up to 1,500 additional patients, representing the Company's continued commitment to advancing clinical evidence for the treatment of peripheral artery disease and expanding the clinical applications for the Auryon platform.

First Patient Enrolled in RECOVER-AV Clinical Trial

During the quarter, the Company announced the first patient enrollment in the RECOVER-AV clinical trial, a prospective, multi-center, multi-national, single-arm study evaluating the AlphaVac F1885 System for the treatment of acute, intermediate-risk pulmonary embolism. The study builds on the existing U.S. FDA 510(k) clearance and European CE Mark approval to assess mechanical thrombectomy treatment and long-term functional outcomes in intermediate-risk PE patients across Europe, Canada, and Hong Kong. The trial will enroll patients at up to 20 hospital-based sites and follows patients for 12 months, with functional and quality-of-life outcomes assessed at 30 days and 12 months, representing the Company's continued commitment to expanding its global clinical presence and generating evidence-based data to support broader access to life-saving PE treatment.

NanoKnife PRESERVE Study Results Published in Leading European Journal

During the quarter, the Company announced the publication of results from the PRESERVE study in European Urology, a leading journal in urologic research. The study assessed the safety and effectiveness of irreversible electroporation with the NanoKnife System to ablate prostate tissue in patients with intermediate-risk prostate cancer. The PRESERVE clinical study met its primary effectiveness endpoint, with 84.0% of men free from in-field, clinically significant disease at 12 months post-procedure. The study also demonstrated strong quality-of-life outcomes, with urinary continence largely preserved (97% at baseline vs. 96% at 12 months) and 84% of patients with good baseline sexual function at 12 months, reinforcing the NanoKnife System's role in providing effective treatment while preserving quality of life.

Fiscal Year 2026 Financial Guidance

For fiscal year 2026 the company now expects:

Guidance Metric

Guidance Action

Current Guidance

(as of October 2, 2025)

Previous Guidance

(as of July 15, 2025)

Net Sales

Increased

$308 - $313 million

$305 - $310 million

Med Tech Net Sales Growth

Increased

14% - 16%

12% - 15%

Med Device Net Sales Growth

Unchanged

Flat

Flat

Gross Margin

Unchanged

53.5% - 55.5%

53.5% - 55.5%

Adjusted EBITDA

Increased

$6.0 - $10.0 million

$3.0 - $8.0 million

Adjusted EPS

Increased

($0.33) – ($0.23)

($0.35) – ($0.25)

Free Cash Flow

Unchanged

Positive for full year FY 2026

Positive for full year FY 2026

Tariff Related Guidance Assumptions

For the full fiscal year 2026, the company continues to expect a $4.0 - $6.0 million impact from tariffs, which are included in the above provided guidance.

All assumptions made related to expected tariff impacts are based on the Company’s point of view on the current tariff situation, as of October 2, 2025. As the situation is fluid, these assumptions may change in the future.

Conference Call

The Company’s management will host a conference call at 8:00 a.m. ET the same day to discuss the results. To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international). This conference call will also be webcast and can be accessed from the “Investors” section of the AngioDynamics website at www.angiodynamics.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

A recording of the call will also be available, until Thursday, October 09, 2025 at 11:59 PM ET. To hear this recording, dial 1-844-512-2921 (domestic) or +1-412-317-6671 (international) and enter the passcode 13755707.

Use of Non-GAAP Measures

Management uses non-GAAP measures to establish operational goals and believes that non-GAAP measures may assist investors in analyzing the underlying trends in AngioDynamics' business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this news release, AngioDynamics has reported pro forma results, adjusted EBITDA, adjusted net income and adjusted earnings per share. Management uses these measures in its internal analysis and review of operational performance. Management believes that these measures provide investors with useful information in comparing AngioDynamics' performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics' underlying business. Management encourages investors to review AngioDynamics' financial results prepared in accordance with GAAP to understand AngioDynamics' performance taking into account all relevant factors, including those that may only occur from time to time but have a material impact on AngioDynamics' financial results. Please see the tables that follow for a reconciliation of non-GAAP measures to measures prepared in accordance with GAAP.

About AngioDynamics, Inc.

AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients.

The Company’s innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, visit www.angiodynamics.com.

Safe Harbor

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "projects," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics' expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, tariffs, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain regulatory clearances or approval of its products, or to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2025. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

Three Months Ended

As Reported (1)

Pro Forma Adjustments (2)

Pro Forma

Aug 31, 2025

Aug 31, 2024

Aug 31, 2024

Aug 31, 2024

(unaudited)

Net sales

$

75,711

$

67,491

9

$

67,500

Cost of sales (exclusive of intangible amortization)

33,854

30,767

(2

)

30,765

Gross margin

41,857

36,724

11

36,735

% of net sales

55.3

%

54.4

%

54.4

%

Operating expenses

Research and development

6,417

6,285

—

6,285

Sales and marketing

28,130

25,605

—

25,605

General and administrative

12,555

10,975

—

10,975

Amortization of intangibles

2,653

2,570

—

2,570

Change in fair value of contingent consideration

—

76

—

76

Acquisition, restructuring and other items, net

2,758

4,311

154

4,465

Total operating expenses

52,513

49,822

154

49,976

Operating loss

(10,656

)

(13,098

)

(143

)

(13,241

)

Interest income (expense), net

(4

)

606

—

606

Other expense, net

(178

)

(173

)

—

(173

)

Total other income (expense), net

(182

)

433

—

433

Loss before income tax benefit

(10,838

)

(12,665

)

(143

)

(12,808

)

Income tax expense

65

133

—

133

Net loss

$

(10,903

)

$

(12,798

)

$

(143

)

$

(12,941

)

Loss per share

Basic

$

(0.26

)

$

(0.31

)

$

(0.32

)

Diluted

$

(0.26

)

$

(0.31

)

$

(0.32

)

Weighted average shares outstanding

Basic

41,174

40,653

40,653

Diluted

41,174

40,653

40,653

Reconciliation of Net Loss to non-GAAP Adjusted Net Loss and Pro Forma Adjusted Net Loss:

Three Months Ended

As Reported (1)

Pro Forma Adjustments (2)

Pro Forma

Aug 31, 2025

Aug 31, 2024

Aug 31, 2024

Aug 31, 2024

(unaudited)

Net loss

$

(10,903

)

$

(12,798

)

$

(143

)

$

(12,941

)

Amortization of intangibles

2,653

2,570

—

2,570

Change in fair value of contingent consideration

—

76

—

76

Acquisition, restructuring and other items, net (3)

2,758

4,311

154

4,465

Tax effect of non-GAAP items (4)

1,313

1,446

(3

)

1,443

Adjusted net loss

$

(4,179

)

$

(4,395

)

$

8

$

(4,387

)

Reconciliation of Diluted Loss and Pro Forma Diluted Loss Per Share to non-GAAP Adjusted and Pro Forma Adjusted Diluted Loss Per Share:

Three Months Ended

As Reported (1)

Pro Forma Adjustments (2)

Pro Forma

Aug 31, 2025

Aug 31, 2024

Aug 31, 2024

Aug 31, 2024

(unaudited)

Diluted loss per share

$

(0.26

)

$

(0.31

)

$

(0.01

)

$

(0.32

)

Amortization of intangibles

0.06

0.06

0.00

0.06

Change in fair value of contingent consideration

0.00

0.00

0.00

0.00

Acquisition, restructuring and other items, net (3)

0.07

0.10

0.00

0.10

Tax effect of non-GAAP items (4)

0.03

0.04

0.00

0.04

Adjusted diluted loss per share

$

(0.10

)

$

(0.11

)

$

0.00

$

(0.11

)

Adjusted diluted sharecount (5)

41,174

40,653

40,653

40,653

Reconciliation of Net Loss and Pro Forma Net Loss to Adjusted EBITDA and Pro Forma Adjusted EBITDA:

Three Months Ended

As Reported (1)

Pro Forma Adjustments (2)

Pro Forma

Aug 31, 2025

Aug 31, 2024

Aug 31, 2024

Aug 31, 2024

(unaudited)

Net loss

$

(10,903

)

$

(12,798

)

$

(143

)

$

(12,941

)

Income tax expense

65

133

—

133

Interest expense (income), net

4

(606

)

—

(606

)

Depreciation and amortization

5,950

6,785

—

6,785

Change in fair value of contingent consideration

—

76

—

76

Stock based compensation

4,470

3,205

—

3,205

Acquisition, restructuring and other items, net (3)

2,574

3,042

154

3,196

Adjusted EBITDA

$

2,160

$

(163

)

$

11

$

(152

)

Three Months Ended

(in thousands)

Aug 31, 2025

Aug 31, 2024

Legal (1)

$

213

$

507

Plant closure (2)

2,345

3,589

Transition service agreement (3)

(302

)

(507

)

Other

502

722

Total

$

2,758

$

4,311

 

(1) Legal expenses related to litigation that is outside the normal course of business.

(2) Plant closure expense, related to the restructuring of our manufacturing footprint which was announced on January 5, 2024.

(3) Transition services agreements that were entered into with Merit and Spectrum.

Three Months Ended

As Reported (1)

Pro Forma

Adjustments (2)

Pro Forma

Actual

Pro Forma

Aug 31, 2025

Aug 31, 2024

Aug 31, 2024

Aug 31, 2024

% Growth

% Growth

(unaudited)

Net Sales

Med Tech

$

35,261

$

27,969

$

—

$

27,969

26.1

%

26.1

%

Med Device

40,450

39,522

9

39,531

2.3

%

2.3

%

$

75,711

$

67,491

$

9

$

67,500

12.2

%

12.2

%

Net Sales

United States

$

66,456

$

59,481

$

10

$

59,491

11.7

%

11.7

%

International

9,255

8,010

(1

)

8,009

15.5

%

15.6

%

$

75,711

$

67,491

$

9

$

67,500

12.2

%

12.2

%

GROSS MARGIN BY PRODUCT CATEGORY

(in thousands)

 

Three Months Ended

As Reported (1)

Pro Forma

Adjustments (2)

Pro Forma

Actual

Pro Forma

Aug 31, 2025

Aug 31, 2024

Aug 31, 2024

Aug 31, 2024

% Change

% Change

(unaudited)

(unaudited)

Med Tech

$

21,922

$

17,697

$

—

$

17,697

23.9

%

23.9

%

Gross margin % of sales

62.2

%

63.3

%

63.3

%

Med Device

$

19,935

$

19,027

$

11

$

19,038

4.8

%

4.7

%

Gross margin % of sales

49.3

%

48.1

%

48.2

%

Total

$

41,857

$

36,724

$

11

$

36,735

14.0

%

13.9

%

Gross margin % of sales

55.3

%

54.4

%

54.4

%

Aug 31, 2025

May 31, 2025

(unaudited)

(audited)

Assets

Current assets:

Cash and cash equivalents

$

38,762

$

55,893

Accounts receivable, net

42,643

42,890

Inventories

62,255

62,006

Prepaid expenses and other

12,996

7,535

Total current assets

156,656

168,324

Property, plant and equipment, net

31,066

32,300

Other assets

9,540

10,404

Intangible assets, net

68,380

69,116

Total assets

$

265,642

$

280,144

Liabilities and stockholders' equity

Current liabilities:

Accounts payable

$

31,882

$

33,291

Accrued liabilities

27,657

35,518

Other current liabilities

8,743

7,388

Total current liabilities

68,282

76,197

Deferred income taxes

4,268

4,073

Other long-term liabilities

14,237

16,904

Total liabilities

86,787

97,174

Stockholders' equity

178,855

182,970

Total Liabilities and Stockholders' Equity

$

265,642

$

280,144

Three Months Ended

Aug 31, 2025

Aug 31, 2024

(unaudited)

Cash flows from operating activities:

Net loss

$

(10,903

)

$

(12,798

)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization

6,020

6,785

Non-cash lease expense

445

494

Stock based compensation

4,470

3,205

Change in fair value of contingent consideration

—

76

Deferred income taxes

(16

)

(339

)

Change in accounts receivable allowances

108

270

Fixed and intangible asset impairments and disposals

(27

)

20

Other

264

121

Changes in operating assets and liabilities:

Accounts receivable

139

3,784

Inventories

(192

)

(4,053

)

Prepaid expenses and other

(5,525

)

(836

)

Accounts payable, accrued and other liabilities

(10,697

)

(14,982

)

Net cash used in operating activities

(15,914

)

(18,253

)

Cash flows from investing activities:

Additions to property, plant and equipment

(731

)

(1,092

)

Additions to placement and evaluation units

(820

)

(1,313

)

Net cash used in investing activities

(1,551

)

(2,405

)

Cash flows from financing activities:

Principal payments on finance arrangements

(91

)

—

Repurchase of common stock

—

(552

)

Proceeds from exercise of stock options and employee stock purchase plan

234

43

Net cash provided by (used in) financing activities

143

(509

)

Effect of exchange rate changes on cash and cash equivalents

191

116

Decrease in cash and cash equivalents

(17,131

)

(21,051

)

Cash and cash equivalents at beginning of period

55,893

76,056

Cash and cash equivalents at end of period

$

38,762

$

55,005

More News From AngioDynamics, Inc.

STAFFORD, Texas, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the expansion of FLAMINGO-01 clinical trial to Belgium.

The Company's application to European regulators has been formally approved, adding Belgium as an approved country in FLAMINGO-01 in addition to Spain, France, Germany, Italy, Poland, Romania, Ireland, Portugal, and the US.

According to the latest data collected by the European Cancer Information System (click here), a total of 11,366 new cases of breast cancer were diagnosed in Belgium in 2022, which is the most common cancer diagnosed in women, representing approximately 33% of all cancers in women. Breast cancer is the leading cause of death from cancer in women in Belgium with 2,324 deaths in 2022.

The Company is collaborating with Patrick Neven, MD, PhD, at UZ Leuven, who will be serving as the national principal investigator in Belgium for FLAMINGO-01. Dr Neven is Full Professor at the Department of Gynecological Oncology, University Hospitals Leuven, and is a staff member of the Multidisciplinary Breast Centre. His research focuses on breast oncology, particularly endocrine therapy and quality of life. He has served as principal investigator in multiple clinical trials, published over 300 peer-reviewed papers, and lectured widely at international meetings. He is president of the Belgian Society of Senology, active in several scientific societies, and has mentored numerous doctors and PhD students in breast cancer care.

CEO Snehal Patel commented, "We thank our steering committee for introducing us to Dr. Neven and look forward to working with him and his colleagues. We are planning start-up activities in Leuven in the coming month. Leuven is centrally located in Belgium and is an ideal location to cover large parts of the country, including Brussels and Antwerp."

About FLAMINGO-01 and GLSI-100

FLAMINGO-01 (NCT05232916) is a Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients who had residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant trastuzumab based treatment. The trial is led by Baylor College of Medicine and currently includes US and European clinical sites from university-based hospitals and academic and cooperative networks with plans to open up to 150 sites globally. In the double-blinded arms of the Phase III trial, approximately 500 HLA-A*02 patients will be randomized to GLSI-100 or placebo, and up to 250 patients of other HLA types will be treated with GLSI-100 in a third arm. The trial has been designed to detect a hazard ratio of 0.3 in invasive breast cancer-free survival, where 28 events will be required. An interim analysis for superiority and futility will be conducted when at least half of those events, 14, have occurred. This sample size provides 80% power if the annual rate of events in placebo-treated subjects is 2.4% or greater.

For more information on FLAMINGO-01, please visit the Company's website here and clinicaltrials.gov here. Contact information and an interactive map of the majority of participating clinical sites can be viewed under the "Contacts and Locations" section. Please note that the interactive map is not viewable on mobile screens. Related questions and participation interest can be emailed to: [email protected]

About Breast Cancer and HER2/neu Positivity

One in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 300,000 new breast cancer patients and 4 million breast cancer survivors. HER2 (human epidermal growth factor receptor 2) protein is a cell surface receptor protein that is expressed in a variety of common cancers, including in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels.

About Greenwich LifeSciences, Inc.

Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. Greenwich LifeSciences has commenced a Phase III clinical trial, FLAMINGO-01. For more information on Greenwich LifeSciences, please visit the Company's website at www.greenwichlifesciences.com and follow the Company's Twitter at https://twitter.com/GreenwichLS.

Forward-Looking Statement Disclaimer

Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Greenwich LifeSciences Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including statements regarding the intended use of net proceeds from the public offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section entitled "Risk Factors" in Greenwich LifeSciences' Annual Report on the most recent Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law.

Company Contact
Snehal Patel
Investor Relations
Office: (832) 819-3232
Email: [email protected]

Investor & Public Relations Contact for Greenwich LifeSciences
Dave Gentry
RedChip Companies Inc.
Office: 1-800-RED CHIP (733 2447)
Email: [email protected]

Calgary, Alberta--(Newsfile Corp. - October 2, 2025) - Argyle Resources Corp. (CSE: ARGL) (OTCQB: ARLYF) (FSE: ME0) ("Argyle" or the "Company") is pleased to provide an update on its ongoing diamond drilling program at the Clay Howells Rare Earth Element (REE) Project, located in northwestern Ontario. The campaign has completed four holes, and drilling is now underway on the fifth.

October 02, 2025 6:00 AM EDT | Source: Dryden Gold Corp.
Vancouver, British Columbia--(Newsfile Corp. - October 2, 2025) - Dryden Gold Corp. (TSXV: DRY) (OTCQB: DRYGF) (FSE: X7W) ("Dryden Gold" or the "Company") is pleased to discuss the assay results from the summer channeling program at the Company's Hyndman project. A high-grade interval of 23.32 g/t gold over 2.80 meters, including 24.79 g/t gold over 1.50 meters also including 36.90 g/t gold over 0.70 meters has resulted in a positive drill-test decision as part of Dryden Gold's fully funded 2026 exploration program. Hyndman is located on the eastern portion of Dryden Gold's large land package (Figure 1).

Maura Kolb, President of Dryden Gold states, "Advancing the Hyndman target was one of our four main objectives for the 2025 Exploration Campaign. Making a new discovery there is an exciting validation of our two-pronged approach to our district-wide exploration strategy After a recent site visit, with the new results in hand, I was very pleased to observe the significant vein-shear gold-bearing relationship of the gold bearing structures. Pending assays from our property-wide soil-till sampling will also help us vector into additional potential targets of similar mineralization within the 5-kilometer strike potential at Hyndman."

Regional work at Hyndman is part of the Company's two-pronged approach to exploration in the Dryden Gold District (see video summary here). First and foremost, the Company is focused on its flagship brownfields prospect at the Gold Rock Target Area ("Gold Rock"). Drilling at Gold Rock has intercepted multiple high-grade parallel structures over a one-kilometer strike. In addition, Dryden Gold intends to make new discoveries through regional exploration which includes: (1) proving periodicity in the Gold Rock Camp with a 2-kilometer step-out at Mud Lake, (2) drill testing the Sherridon Project and (3) advancing the Hyndman Project to "drill-ready" status through channel sampling. Drilling at Mud Lake and Sherridon and extensional drill testing along the Elora structure in the Gold Rock Target Area have been completed with results pending.

"The mineralization that we are observing at Hyndman appears to be very similar to the Goldlund Deposit held by NexGold," commented CEO Trey Wasser, "Goldlund is located within the Dryden Region. What excites me the most is that the host rock for Hyndman has 4-5 times more potential strike length than Goldlund. In addition, Hyndman is located right off the Trans-Canada Highway, which has extensive logging road access, railway crossing the property and Ontario grid power. The Team is now combining our summer mapping and prospecting with the channel sample results to refine our geologic understanding and prepare for Hyndman's drilling phase."

Dryden first announced positive assay results at Hyndman from the 2023 reconnaissance program where the target was first discovered (January 25, 2024). This first significant assay result on the Hyndman project was followed up with a detailed mapping and sampling program in 2024 (January 13, 2025). Previous assay results from Hyndman were all surface grab samples. This current program utilized channel sampling which cuts the rock on surface. Channel samples are taken by cutting parallel cuts along the surface of the rock then chipping out the rock in between. This creates a continuous sample across the geological features similar to a drill hole. The new results of 23.32 g/t gold over 2.80 meters, including 24.79 g/t gold over 1.50 meters also including 36.90 g/t gold over 0.70 meters was hosted in a shear-vein at surface (Figure 2). See summary video here.

Figure 1: Map showing location of Hyndman

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/9776/268827_d3f8afec7438fb73_001full.jpg

Geology Summary

Hyndman is in the Kawashegamuk Group, with various lithologies of metasedimentary units within the larger mafic metavolcanic sequences, often displaying massive to pillowed basalts, and various lenses of intermediate intrusions. The current Hyndman target is a large, roughly, 4-5 km long and 400m wide (at the widest section), oblong, diorite intrusion marginally situated south-west of an interpreted 1.8 km wide deformation interpreted from strongly elongate pillowed basalts containing garnet in the selvages indicating increased pressure and fluid flow, in alternance with thickly laminated clastic metasedimentary units.

Within this large diorite, discrete 1 to 5-meter shear zones (variable thickness defined by surface expression) typically contain small mm to cm sized boudinaged quartz veinlets parallel to the shear fabric, oriented NW-SE, with visible 20 — 30cm sized quartz veins containing up to 5% visible Py, also shear-parallel. Hematite-ankerite staining and alteration is stronger marginal to the larger and more prominent quartz-veins and veinlets. It appears that the rheological change from the surrounding volcanic rock to the intermediate intrusion was favorable for gold deposition during this deformational event. The Company's geological interpretation is on-going following completion of our fieldwork program and drill testing using oriented core.

Figure 2: Map showing highlight results from Hyndman

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/9776/268827_d3f8afec7438fb73_002full.jpg

Table 1: Highlight results from Hyndman Channel Sample Program

Target AreaChannel ID
FromTo Length (m)Grade (g/t Au)Hyndman South
 Intrusion-HostedDHY-CH-045
3.906.702.8023.32incl.4.205.701.5024.79incl.5.005.700.7036.90Hyndman South
Mafic hostedDHY-CH-063
1.002.001.002.37Hyndman North
 Intrusion-HostedDHY-CH-001
0.001.001.001.66Hyndman North
 Mafic hostedDHY-CH-059
7.007.700.702.12DHY-CH-080
0.001.001.001.85DHY-CH-126
1.002.001.001.10*Reported intervals are drilled core lengths; assay values are uncutMarketing Update
Management will be participating in the upcoming 121 Global Online Conference taking place on October 14-15, 2025. Investors can look forward to getting an update on our fully funded drill program and upcoming exploration plans. We welcome investors to reach out for meetings and to review our updated corporate presentation, here. For more information about which conferences management will be attending next, please visit our Events page, here.

Qualified Person
The technical disclosure in this news release has been reviewed and approved by Maura J. Kolb, M.Sc., P. Geo., President of Dryden Gold and a Qualified Person as defined by National Instrument 43-101 of the Canadian Securities Administrators.

Analytical Laboratory and QA/QC Procedures
The Company is drilling NQ size core. Samples are cut in half, with half going to the lab for analysis and half kept as a record. True thickness/widths of the mineralization are unknown, result intervals are reported as the drilled core lengths unless otherwise stated. All sampling completed by Dryden Gold Corp. within its exploration programs is subject to a Company standard of internal quality control and quality assurance (QA/QC) programs which include the insertion of certified reference materials, blank materials, and a level of duplicate analysis. Drill samples from the 2024 and 2025 program were sent to Activation Laboratories, with sample preparation and analysis in Dryden, where they were processed for gold analysis by 50-gram fire assay with an atomic absorption finish and over limits determined by Fire Assay with a gravimetric finish. Select samples were analyzed using metallic screens. Activation Laboratories systems conform to requirements of ISO/IEC Standard 17025 guidelines and meets assay requirements outlined for NI 43-101.

ABOUT DRYDEN GOLD CORP.
Dryden Gold Corp. is an exploration company focused on the discovery of high-grade gold mineralization listed on the TSX Venture Exchange ("DRY") and on the OTCQB marketplace ("DRYGF") and FSE ("X7W"). The Company has a strong management team and Board of Directors comprised of experienced individuals with a track record of building shareholder value through property acquisition and consolidation, exploration success, and mergers and acquisitions. Dryden Gold controls a 100% interest in a dominant strategic land position in the Dryden Gold District of Northwestern Ontario. Dryden Gold's property package includes historic gold mines but has seen limited modern exploration. The property hosts high-grade gold mineralization over 50km of potential strike length along the Manitou-Dinorwic deformation zone. The property has excellent infrastructure, enjoys collaborative relationships with First Nations communities and benefits from proximity to an experienced mining workforce.

For more information go to our website www.drydengold.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements
The information contained herein contains "forward-looking statements" within the meaning of applicable securities legislation. Forward-looking statements include, but are not limited to, statements with respect to the acquisition of the Property, receipt of corporate and regulatory approvals, issuance of common shares; future development plans; future acquisitions; exploration programs; and the business and operations of Dryden Gold. Forward-looking statements relate to information that is based on assumptions of management, forecasts of future results, and estimates of amounts not yet determinable. Any statements that express predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be "forward-looking statements." Forward-looking statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ from those reflected in the forward-looking statements, including, without limitation: risks related to failure to obtain adequate financing on a timely basis and on acceptable terms; risks related to the outcome of legal proceedings; political and regulatory risks associated with mining and exploration; risks related to the maintenance of stock exchange listings including receipt of TSX Venture Exchange approval for the acquisition of the Property; risks related to environmental regulation and liability; the potential for delays in exploration or development activities; the uncertainty of profitability; risks and uncertainties relating to the interpretation of drill results, the geology, grade and continuity of mineral deposits; risks related to the inherent uncertainty of production and cost estimates and the potential for unexpected costs and expenses; the possibility that future exploration, development or mining results will not be consistent with the Company's expectations; risks related to commodity price fluctuations; and other risks and uncertainties related to the Company's prospects, properties and business detailed elsewhere in Dryden Gold's and the Company's disclosure record. Should one or more of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in forward-looking statements. Investors are cautioned against attributing undue certainty to forward-looking statements. These forward-looking statements are made as of the date hereof and Dryden Gold and the Company do not assume any obligation to update or revise them to reflect new events or circumstances. Actual events or results could differ materially from Dryden Gold's and the Company's expectations or projections.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/268827

EAGLE, Idaho, Oct. 02, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice, home care and senior living companies, announced today that on October 1, 2025, it acquired certain operations from UnitedHealth Group Incorporated (“UnitedHealth”). The operations were divested pursuant to UnitedHealth’s and Amedisys Inc.’s (“Amedisys”) antitrust settlement with the United States Justice Department.

Pennant is purchasing divested home health, hospice, and personal care services in Tennessee, Georgia and Alabama for a combined purchase price of $146.5 million. The asset package includes 54 locations.

The acquired agencies are primarily located in Tennessee, a certificate of need state. Approximately two-thirds of the revenue is connected to home health and one-third to hospice. Pennant and UnitedHealth have a transition services agreement in place to facilitate a smooth transition, and Pennant has prepared throughout 2025 to execute on the transaction.

“This marks an exciting new chapter in Pennant’s growth journey,” said Brent Guerisoli, Pennant's Chief Executive Officer. “Entering the Southeast is a strategic move for us, and we do so from a position of strength, building on proven leadership, operational excellence, and a clear vision for the future. This acquisition opens the door for emerging leaders in this new region to grow within Pennant’s innovative platform.”

“We are pleased to welcome these exceptional teams into the Pennant family,” said John Gochnour, Pennant’s Chief Operating Officer. “They are among the leading operators in our industries, and their commitment to clinical excellence and deep local ties to the region make this an exciting combination. We look forward to bringing these agencies into our portfolio and bringing the Pennant operating model to the Southeast United States.”

Mr. Guerisoli reiterated that Pennant will continue to pursue opportunities for growth in the home health, hospice and senior living industries, targeting strategic and underperforming operations of all sizes.

Pennant was advised on legal matters by Robinson & Cole LLP and Paul Hastings LLP, with Truist Securities serving as financial advisor on the transaction.

About Pennant:

The Pennant Group, Inc. is a holding company of independent operating subsidiaries that provide healthcare services through home health and hospice agencies and senior living communities located throughout Arizona, California, Colorado, Connecticut, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin and Wyoming. Each of these businesses is operated by a separate, independent operating subsidiary that has its own management, employees and assets. References herein to the consolidated "company" and "its" assets and activities, as well as the use of the terms "we," "us," "its" and similar verbiage, are not meant to imply that The Pennant Group, Inc. has direct operating assets, employees or revenue, or that any of the home health and hospice businesses, senior living communities or the Service Center are operated by the same entity. More information about Pennant is available at www.pennantgroup.com.

SOURCE: The Pennant Group, Inc.

Highlights: US Tariffs: Immuron does not anticipate any material impact from the recently announced US tariffs on pharmaceutical products Travelan® Clinical Study: Topline results from the Travelan® clinical study conducted by Uniformed Services University are anticipated in October 2025 IMM-529 Regulatory Milestone: Immuron plans to submit an Investigational New Drug (IND) application to the U.S. FDA for IMM-529 (Clostridiodes difficile infection) in mid-October 2025 ProIBS® Commercial Launch: The Australian Launch of ProIBS® is on track for Q4 of calendar year 2025 IMM-986 Pre-Clinical Progress: Initial pre-clinical research studies for IMM-986, targeting Vancomycin-resistant Enterococci (VRE), are anticipated to be completed by year-end 2025 MELBOURNE, Australia, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to provide shareholders with a brief update on progress with a number of projects. Sales As announced on July 17, Immuron achieved record sales up to Financial Year ending June 30, 2025.Immuron is on track to exceed FY24 first quarter sales.

TOMBALL, Texas--(BUSINESS WIRE)--O2 Investment Partners (www.o2investment.com) is pleased to announce that through Centex Construction (“Centex”) (www.centexconstruction.com), a leading provider of renovation, restoration, and maintenance services for the multi-family facility market, it has made an investment in and partnered with One Way Property Restoration (“One Way”) (www.oneway.com) to support its strategic growth plan.

We are excited to work alongside Jason, Joshua, and the One Way team. Their expertise, capabilities, and entrenched customer relationships are accretive to Centex, and strengthen the platform’s emergency mitigation and restoration service mix.

Share
Founded in 2001 by Jason Dupuis and later joined by Joshua Rafter, One Way is an established provider of 24/7 emergency mitigation and restoration services for water and fire damage, mold remediation, reconstruction, and carpet cleaning services primarily serving the multi-family and commercial end markets. One Way is based in Tampa, Florida, and maintains additional locations in Washington, Michigan, Indiana, and Maryland.

“We are excited to partner with One Way,” said Mark Whitehead, President of Centex. “Jason and Joshua have built an outstanding business with a diversified customer base, unique service offering, and geographic presence that aligns well with and broadens the platform’s footprint. We look forward to providing resources and infrastructure to support One Way’s continued success.”

“Partnering with Centex and O2 is a tremendous opportunity to accelerate the future growth of both businesses. One Way now has an additional suite of services that we can deliver to our customers through Centex’s renovation and maintenance capabilities, while Centex gains additional restoration capacity and access to four new geographic markets,” said Jason Dupuis, President of One Way. “Centex is an outstanding fit for our company, and we are thrilled to partner with Mark and his team as we embark on this next chapter.”

Charlie Miller at O2 commented, “We are excited to work alongside Jason, Joshua, and the One Way team. Their expertise, capabilities, and entrenched customer relationships are accretive to Centex, and strengthen the platform’s emergency mitigation and restoration service mix. This partnership expands our total addressable market, creates significant cross-selling opportunities, and enhances our position as a leader in the multi-family services sector.”

About Centex Construction

Headquartered in Tomball, TX and founded in 2016, Centex Construction is a leading provider of renovation, restoration, and maintenance services for existing, largescale multi-family property managers and owners. The Company’s operations span 8 states across the Southeast and Southwest United States. Centex offers a comprehensive suite of services, including immediate maintenance repair, exterior renovations, roofing, restoration and rebuild, interior renovations, and amenity upgrades, among other services. Centex completes thousands of jobs annually with many of the largest nationally recognized property managers and owners in the United States. Additional information is available at www.centexconstruction.com.

About One Way

One Way is an established provider of 24/7 emergency mitigation and restoration services for water and fire damage, mold remediation, reconstruction, and carpet cleaning services primarily serving the multi-family and commercial end markets. One Way is based in Tampa, Florida, and maintains additional locations in Washington, Michigan, Indiana, and Maryland. Additional information is available at www.oneway.com.

About O2 Investment Partners

O2 Investment Partners is a Midwestern based private equity firm that seeks to invest in lower middle market B2B services, technology, and select industrial companies. The firm invests in businesses with earnings growth potential and a clear path to the creation of shareholder value. O2 invests with a view toward partnering with management to build and grow the business and take it to its next stage of development. This requires not only a clear vision and strategic plan to create shareholder value, but a close partnership and alignment of interest with management. Additional information is available at www.o2investment.com.

, /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) will release its third quarter 2025 financial results on Thursday, October 30, 2025, and will host a conference call the same day.

Third quarter 2025 financial results will be released no later than 6:30 a.m. Eastern Time (ET). Management will review these results on a conference call beginning at 8:30 a.m. ET. The call-in numbers are as follows:

               Live Call
               (888) 566-1889 (Domestic)
               (773) 799-3989 (International)
               Passcode: 10302025

               Replay
               (866) 405-7290 (Domestic)
               (203) 369-0603 (International)

It is strongly suggested that participants dial in to the conference call by 8:15 a.m. ET on October 30, 2025. A replay of the call will be available from 12:30 p.m. ET on October 30, 2025 until 10:59 p.m. ET on November 13, 2025. Additionally, the conference call will be available on a live internet webcast at https://investors.thecignagroup.com/events-and-presentations/default.aspx in the Investor Relations section of The Cigna Group's website. Please note that this feature will be in listen-only mode.

A copy of the company's news release and financial supplement will be available on The Cigna Group's website in the Investor Relations section at https://investors.thecignagroup.com/overview/default.aspx, no later than 6:30 a.m. ET on October 30, 2025.

About The Cigna Group

The Cigna Group (NYSE:CI) is a global health company committed to creating a better future built on the vitality of every individual and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. The Cigna Group includes products and services marketed under Cigna Healthcare, Evernorth Health Services or its subsidiaries. The Cigna Group maintains sales capabilities in more than 30 markets and jurisdictions, and has approximately 180 million customer relationships around the world. Learn more at thecignagroup.com.

Investor Relations Contact
Ralph Giacobbe
1 (860) 787-7968
[email protected]

Media Contact
Justine Sessions
1 (860) 810-6523
[email protected]

SOURCE The Cigna Group

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Fans can celebrate one of 2025's biggest cultural moments with 200 new 'Wicked' and 'Wicked: For Good' products, with nearly half of the assortment exclusive and priced under $20

Including a collection featuring exclusive apparel and home decor by designer Katie Kime

Pre-orders available today for an exclusive 'Wicked' collector's book featuring a sneak peek at the upcoming film, letters from the leading ladies and images from the film

, /PRNewswire/ -- Target Corporation (NYSE: TGT) today announced an all-new collection inspired by Universal Pictures' "Wicked: For Good." The assortment features nearly 200 new products, with nearly half the assortment exclusive to Target and priced under $20. Fans can shop their favorites and find affordable gift options. The collection will begin rolling out Oct. 5 in Target stores and on Target.com with additional product drops leading up to the film's release only in theaters on Nov. 21.

"Last year, Target was the go-to for all things 'Wicked' and we can't wait to help Glinda and Elphaba fans everywhere celebrate the epic conclusion of this incredible story," said Jill Sando, executive vice president and chief merchandising officer of apparel & accessories, home and hardlines, Target. "We're bringing the magic of a cultural phenomenon to life with an assortment of products featuring great design, beloved brands and incredible value to help everyone embrace the magic of the Land of Oz in a uniquely Target way."

Be changed for good with a spellbinding collection 
In the lead-up to the beloved film's sequel premiere, Target will be the go-to destination for products spanning apparel, books, home decor, toys and more that can't be found anywhere else, including:

"Wicked: For Good" x Katie Kime Collection  – A line blending bold design and whimsical storytelling to reimagine the "Wicked" universe for wardrobes and homes. Known for her vibrant prints and lifestyle goods, Katie Kime brings the visual magic of "Wicked" into everyday life with two Target exclusives: a home décor collection launching Oct. 12, followed by an apparel and accessories collection on Nov. 2.
"Wicked": The Official Visual Companion – An exclusive collector's book featuring personal letters from cast members, a limited-edition reversible poster and more than 300 full-color images. The book is available for preorder on Target.com now, and in stores and online beginning Nov. 21.
"Wicked: For Good" – The Soundtrack – A Target exclusive LP vinyl featuring a lenticular cover and pink and green shimmer vinyl. With fan-favorite music and lyrics by legendary Grammy and Oscar winning composer and lyricist Stephen Schwartz, the soundtrack includes two new original songs featured in the film: "No Place Like Home" performed by Academy Award nominee Cynthia Erivo as Elphaba, and "The Girl In The Bubble" performed by Academy Award nominee Ariana Grande as Glinda.
Fan-favorite toys and collectibles – Must-have finds including an exclusive LEGO set, Little People figures, Mattel Singing Dolls and Stanley 1913 tumblers round out the assortment, offering fans fun and collectible ways to celebrate the world of "Wicked: For Good."

"Translating the fantastical world of 'Wicked' into Katie Kime prints and products for Target has been an extraordinary honor," states Katie Kime, founder, CEO & designer. "Through vibrant color, imaginative creatures, and beloved characters, this 'Wicked: For Good' x Katie Kime for Target collection captures the spirit of the iconic story I hope fans will love and give a meaningful way to bring the magic of the wonderful world of Elphaba, Glinda and all of Oz into their everyday lives through sleepwear, apparel, and pieces for the home."

A 'Wicked: For Good' experience in stores and online
Fans can gear up and shop "Wicked: For Good" products throughout Target stores and a dedicated "Wicked" destination on Target.com, making it simple to shop, browse and preorder exclusives. Guests can also take advantage of Target's flexible fulfillment services for quicker options, including Same Day Delivery, Drive Up and Order Pickup available within hours, plus Next-Day Delivery or 2-Day Shipping for free with orders above $35.

Additional information about the partnership, along with multimedia downloads of the products, is available on Target's corporate website. Visit the retailer's holiday press hub for more on all the ways Target is delivering savings, ease and holiday magic this season.

About Target
Minneapolis-based Target Corporation (NYSE: TGT) serves guests at nearly 2,000 stores and at Target.com, with the purpose of helping all families discover the joy of everyday life. Since 1946, Target has given 5% of its profit to communities, which today equals millions of dollars a week. Additional company information can be found by visiting the corporate website and press center.

About 'Wicked: For Good'
Last year's global cinematic cultural sensation, which became the most successful Broadway film adaptation of all time, now reaches its epic, electrifying, emotional conclusion. The final chapter of the untold story of the witches of Oz begins with Elphaba (Oscar® nominee Cynthia Erivo) and Glinda (Oscar® nominee Ariana Grande) estranged and living with the consequences of their choices. When a girl from Kansas comes crashing into their lives, they will need to come together one final time, and truly see each other, if they are to change themselves, and all of Oz, for good. 

About Universal Products & Experiences
Universal Products & Experiences (UP&E) globally drives the expansion and elevation of NBCUniversal's iconic collection of brands, intellectual properties, characters, and stories based on the company's extensive portfolio of properties created by Universal Pictures, Illumination, DreamWorks Animation and NBCUniversal Television and Streaming. The division executes this through innovative physical and digital products, as well as engaging retail and product experiences across our expansive global theme park destinations (for both owned and third-party IP), location-based venues, e-commerce product platforms, and retailers around the world. Along with global brand strategy and creative, UP&E's lines of business include Consumer Products and Games, along with Theme Parks Products & Retail. UP&E is a division of Universal Destinations & Experiences, part of NBCUniversal, a subsidiary of Comcast Corporation. More information is available at universalproductsexperiences.com. 

SOURCE Target Corporation

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

The tech conglomerate's American depositary receipts are up 116% so far in 2025.

Francisco Blanch, head of commodities and derivatives research at Bank of America, discusses the power demand from artificial intelligence data centers which have sent wholesale electricity prices to record highs. "Oil is about a third of the energy we consume.

This ETF offers a hefty dividend and the prospect of relatively safe income for decades to come.

The Global X MLP ETF (MLPA 0.21%) boasts a trailing dividend yield of 7.8% and provides passive income-seeking investors with a compelling way to secure quarterly income. Still, yields are far from being the only or the most reliable metric for determining total returns for investors. Let's take a closer look at the ETF and what it has to offer.

What is the Global X MLP ETF?
The ETF invests in master limited partnerships (MLPs) operating in the midstream pipelines and storage facilities industries. MLPs trade publicly, but they carry the benefits of limited partnerships for taxation purposes. MLPs don't pay corporate taxes, so they pass on more of their income to investors in the form of distributions.

Since the ETF only invests in midstream pipeline and storage facility stocks, you can think of the ETF as offering a constant stream of income from its fee-based contracts, whether they be from gas transportation based on volumes of gas, take-or-pay fees, or gas storage fees, directly to the investor in the form of distributions.

Not correlated to energy prices
One of the major drawing points of the ETF is the idea that it invests in stocks that receive a relatively stable level of income based on gas volumes, supported by take-or-pay contracts. As such, the ETF's management claims that the 20 MLPs it invests in "have less sensitivity to energy prices." For reference, the ETF also invests in its sister ETF, the Global X MLP & Energy Infrastructure ETF, which also holds gas pipelines and storage companies, as well as midstream energy infrastructure companies.

Image source: Getty Images.

One way to test the idea that the ETF isn't sensitive to energy prices is by comparing its correlation with that of the oil price and the natural gas price. The result is shown below. As a rough rule of thumb, a figure close to 1 or minus 1 indicates perfect correlation, and a figure of about 0.8 or minus 0.8 indicates strong correlation.

On this basis, the ETF offers the prospect of high income without correlation with energy prices -- something many investors might want, as it means they don't have to take a view on where energy prices are heading.

Fundamental Chart data by YCharts

An alternative viewpoint
That said, it's always essential to understand what viewpoint you are manifesting by buying into an ETF. This is especially important with an ETF, because although the spread of holdings (currently 20) helps diversify stock-specific risk, it locks in risk to the overall investment theme. In other words, you are buying into the idea that gas, and to a lesser extent oil, pipeline, and storage are good industries to invest in.

The following chart shows the total return price. It's a price that assumes reinvestment of the distribution into the ETF and is adjusted to the current price.

The chart illustrates three phases: first, weak performance up to 2020; second, a strong recovery thereafter; and third, a marked period of outperformance from 2024 onward.

MLPA Total Return Price data by YCharts

The first phase took place in a period when optimism over the pace of the energy transition (shift from fossil fuels, such as oil and gas) toward more sustainable fuels, such as renewables, took place. The second phase took place as the recovery from the lockdowns led to a series of supply chain issues and soaring costs for renewable energy, which led to the market negatively reassessing the pace of the transition and recognizing the importance of gas as a source of energy for many decades to come, even as the transition continued.

The third phase occurred as the market priced in the more energy-friendly policies (reducing regulations, unfreezing the export permit pause, and prompting U.S. energy exports) of the Trump administration.

Image source: Getty Images.

A no-brainer investment?
The ETF is not a no-brainer investment, as you must assume that natural gas will continue to play a significant role in the global economy for many years to come and factor in the sector's sensitivity to political developments. While take-or-pay and other long-term customer contracts are fine, the price and willingness to enter them are dictated by demand for energy, and the cost of energy is obviously a function of that.

All told, the ETF is attractive for many reasons, but it's not a no-brainer; investors need to consider how it fits into their portfolios.

Lee Samaha has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Barclays India Chief Economist Aastha Gudwani says RBI's move to ease bank lending norms will accelerate business activity and credit growth, while offering crucial support to exporters. She adds that the reform package unveiled by Governor Sanjay Malhotra in the October policy address was akin to a “mini budget” for the economy.

US consumers face an explosion of online fraud, with surveys showing a growing number of adults experiencing scams or attacks.

Scammers are among the top political ad spenders on Meta's platforms, using deepfake videos of American politicians—including President Donald Trump—to promote fake government benefits, a watchdog group said Wednesday.

The nonprofit Tech Transparency Project said it identified 63 scam advertisers that collectively spent $49 million on Facebook and Instagram, often targeting seniors with ads promoting fake stimulus checks, government spending cards and health care payments.

The ads have reached tens of thousands of the platforms' users.

"The findings show how scammers are taking advantage of advances in artificial intelligence technology, public confusion around the status of social safety net programs, and lax Meta content moderation to target new victims," TTP said in a report.

"Meta is allowing this activity even though it prohibits scams and says it invests in scam prevention to keep users safe," it added.

Meta did not immediately respond to AFP's request for comment.

TTP's report quoted a Meta statement saying that the company would "invest in building new technical defenses" as scammers "constantly evolve their tactics to try to evade detection."

According to Meta's rules, advertisers who seek to run political ads in the United States have to undergo a special authorization process, which involves submitting an official ID such as a driver's license along with a US mailing address.

TTP said all of the 63 scam advertisers—who accounted for over 150,600 political ads—had their advertisements removed by Meta within the past 12 months for violating the tech giant's policies. Still, nearly half of them continued to advertise as of Tuesday.

Meta appeared to disable 35 ad accounts, but only after they ran dozens—and in some cases hundreds—of ads. Six of the accounts spent over $1 million before they were disabled or deleted, the report said.

One advertiser identified by TTP—called the Relief Eligibility Center —- ran an ad on Meta platforms in April and May featuring a deepfake video of Trump falsely promising stimulus checks to Americans.

The video matched a speech by Trump in the White House's Rose Garden in early April, but TTP found that the words in the ad did not match the official transcript from the event.

The ad, which directed users to a website to get a "FREE $5,000 Check from Trump," appeared to target men and women over the age of 65 in more than 20 US states, TTP said.

For years, professional fact-checkers have warned about bogus stimulus check offers circulating on social media platforms.

The latest findings underscore the explosion of online fraud, with surveys showing a growing number of American adults experiencing internet scams or impersonation attacks.

In August, the Federal Trade Commission reported a more than four-fold increase since 2020 in complaints from older adults who lost $10,000 or more—sometimes their entire life savings—to scammers impersonating trusted government agencies or businesses.

© 2025 AFP

New tariffs are quickly rearranging supply chains.

It's only been eight months since President Donald Trump took office, but his tariffs are already rearranging the global supply chain.

While the stock market has recovered from the crash that followed the Liberation Day tariff announcement, individual companies impacted by the tariffs are still scrambling to rearrange their supply chains to respond to the higher import tax rates, which research from The Motley Fool shows here.

RH, the company formerly known as Restoration Hardware, said it was moving production out of China, planning to lower its sourcing from that country to just 2% by the end of the year, and increasing production at its factory in North Carolina.

Image source: Getty Images.

Lululemon is adjusting its e-commerce fulfillment network now that the de minimis exemption, which excluded import taxes on shipments worth less than $800, has been removed.

Reshoring has become a major theme in the evolving supply chain situation as well as a goal of the Trump administration, and while some companies are clearly struggling with the new tariffs, others are poised to benefit. Let's take a look at three of them.

1. Prologis
Real estate investment trusts (REITs) look like a great place to start if you're looking for beneficiaries from the reshoring boom, as it's likely to drive an investment in property.

Prologis (PLD 1.69%), in particular, looks set to be a winner as it's the world's largest owner of logistics real estate or warehouses, contracting with companies like Amazon and FedEx. As companies bring more manufacturing back to the U.S., they will need more warehouses to store and distribute those products. The company also sees demand increasing for facilities in Mexico due to the related trend of nearshoring.

In its second-quarter earnings report, management said its leasing pipeline has reached historically high levels, and it expects strong demand to continue.

The company also raised its guidance for the year due to in-development starts and acquisitions, showing that its expansion efforts are accelerating.

2. Manhattan Associates
Staying in the logistics arena, another company that looks poised to capitalize on the reshoring trend is Manhattan Associates (MANH -2.64%), a maker of logistics software to help businesses manage everything from warehouses to distribution to customer service and sales.

The supply chain changes from the Trump tariffs are likely to drive demand for its services. In fact, one of the companies it's helped is RH, which reduced inventory by 40% and returns by 25% with the help of Manhattan Associates.

Remaining performance obligations, a proxy for backlog, increased 26% in the second quarter, a promising sign for future growth, and should see a steady tailwind as companies adapt to the new trade rules.

3. Intel
Intel (INTC 7.24%) may already be benefiting from the reshoring trend. In fact, maybe more so than any other company, the federal government has been trying to prop up Intel, making it a cornerstone of a renewed American semiconductor manufacturing industry.

Intel won an $8 billion grant from the CHIPS Act, and then Trump took the unusual move of guiding the federal government to take a stake in the company, investing $8.9 billion, which includes some of the CHIPS funding, due to its strategic interest in ensuring that the U.S. has an adequate supply of semiconductors.

Shortly after that announcement, Nvidia took a $5 billion stake in Intel, and Apple was reportedly interested in taking a stake.

Intel may be struggling as the company has been unable to capitalize on the AI boom, as revenue has been flat, and it's losing money. However, the company's long history and its manufacturing assets mean it should continue to attract interest from the U.S. government since reshoring is a top priority.

Jeremy Bowman has positions in Amazon and Nvidia. The Motley Fool has positions in and recommends Amazon, Apple, Intel, Lululemon Athletica Inc., Manhattan Associates, Nvidia, and Prologis. The Motley Fool recommends FedEx and recommends the following options: long January 2026 $90 calls on Prologis and short November 2025 $21 puts on Intel. The Motley Fool has a disclosure policy.

MUNICH--(BUSINESS WIRE)--Advancing the preparation of a digital euro, the European Central Bank (ECB) has announced the conclusion of the framework agreements for each of the five digital euro negotiated procurement procedures (also see the notice view in the Official Journal of the EU). A cooperation between Giesecke+Devrient (G+D) partnering with Nexi and Capgemini has now been selected as the first ranked tenderer in the framework agreement to provide an end-to-end solution to make digital euro payments offline available to users and merchants across Europe. The ability to pay offline, with no third-party involvement, is a key feature of the digital euro, which would ensure privacy and resilience as only cash does today.

A digital euro, issued by the Eurosystem, would be a complement to banknotes and coins, intended to give citizens more freedom of choice when paying digitally in the future. Like cash, it would be available to everyone, at anytime and anywhere as a universally accessible means of payment in the euro area. From the outset, the ECB defined an offline capability as an essential criterion for data privacy and resilience, ensuring payment experiences even in environments without internet connection or power supply. Money is stored directly on users’ devices, such as smartphones, cards and other compatible devices leveraging their secure elements. Payments are settled locally between devices, providing a cash-like privacy as no payment details are recorded by banks, payment service providers or central banks.

Following the completion of negotiated public procurement procedure PRO-009494 Digital Euro Offline Solution, the ECB has now concluded a framework agreement in ranking for the development, implementation and partial operation of the offline solution with a pan-European cooperation as the first-ranked tenderer, led by SecurityTech company G+D, partnering with payment service provider Nexi and global business and technology transformation partner Capgemini. The development refers to the design, definition and implementation of the component and its integration into the overall digital euro architecture.

Following the framework agreement conclusion, G+D and other successful tenderers will work with the ECB to finalize planning and timelines. Under the guidance of the ECB Governing Council and in line with EU legislation, this work will cover the design, integration, and development of the Digital Euro Service Platform (DESP). The cooperation combines G+D's SecurityTech expertise and global experience in public currencies, Capgemini's leadership in technology consulting and digital transformation, and Nexi’s payment technology innovation leadership and POS expertise ensuring integration into the existing infrastructure.

“We are proud to lead this pan-European cooperation, working together with our partners Nexi and Capgemini to bring the digital euro’s offline capabilities to life. This milestone underscores our commitment to innovation and security in digital payment solutions while preserving the privacy and resilience that citizens expect from cash. We are honoured to partner with the European Central Bank in shaping the future of public money for generations to come”, comments Dr. Wolfram Seidemann, CEO of G+D Currency Technology.

“As we accelerate the digitization of payments across Europe, our ambition is to enable solutions that are not only innovative, but also resilient. We’re proud to contribute to the development of such an important part of the infrastructure for the digital euro leveraging our strength and knowledge within acceptance technology, that will help ensure seamless payments, also in situations where the terminal is offline”, comments Renato Martini, Digital Banking Solutions Director of Nexi Group.

“As part of an exclusive team, Capgemini has been selected, in its role as partner of Giesecke+Devrient, to support the ECB in developing the key interfaces and testing the offline functionalities of the digital euro. With in-depth development and testing expertise across various industries, we will ensure seamless implementation of the solutions. This assignment strengthens Capgemini's position as a leading partner for digital transformation in the financial sector. We look forward to working with our valued partners Giesecke+Devrient and Nexi to develop a secure, user-centric and future-proof solution for European payments”, confirms Joachim von Puttkamer, Head of Capgemini’s Financial Services practice in Germany.

About Giesecke+Devrient

Giesecke+Devrient (G+D) is a global SecurityTech company headquartered in Munich, Germany. G+D makes the lives of billions of people more secure. The company shapes trust in the digital age, with built-in security technology in three segments: Digital Security, Financial Platforms and Currency Technology. G+D was founded in 1852 and today has a workforce of more than 14,000 employees. In the fiscal year 2024, the company generated a turnover of 3.1 billion euros. G+D is represented by 118 subsidiaries and joint ventures in 41 countries. Further information: www.gi-de.com.

About Nexi

Nexi is Europe's PayTech company operating in high-growth, attractive European markets, and technologically advanced countries. Listed on Euronext Milan, Nexi has the scale, geographic reach, and abilities to drive the transition to a cashless Europe. With its portfolio of innovative products, e-commerce expertise and industry-specific solutions, Nexi provides flexible support for the digital economy and the entire payment ecosystem globally, across a broad range of different payment channels and methods. Nexi’s technological platform and the best-in-class professional skills in the sector enable the company to operate at its best in three market segments: Merchant Solutions, Issuing Solutions and Digital Banking Solutions. Nexi constantly invests in technology and innovation, focusing on two fundamental principles: meeting, together with its partner banks, customer needs and creating new business opportunities for them. Nexi is committed to supporting people and businesses of all sizes, transforming the way people pay, and businesses accept payments. It offers companies the most innovative and reliable solutions to better serve their customers and expand. By simplifying payments and enabling people and businesses to build closer relationships and grow together, Nexi promotes progress to benefit everyone. Further information: www.nexigroup.com

About Capgemini

Capgemini is a global business and technology transformation partner, helping organizations to accelerate their dual transition to a digital and sustainable world, while creating tangible impact for enterprises and society. It is a responsible and diverse group of 340,000 team members in more than 50 countries. With its strong over 55-year heritage, Capgemini is trusted by its clients to unlock the value of technology to address the entire breadth of their business needs. It delivers end-to-end services and solutions leveraging strengths from strategy and design to engineering, all fuelled by its market leading capabilities in AI, generative AI, cloud and data, combined with its deep industry expertise and partner ecosystem. The Group reported 2024 global revenues of €22.1 billion. Further information: www.capgemini.com

LONDON--(BUSINESS WIRE)--DigitalOcean (NYSE: DOCN), the comprehensive agentic cloud, today announced a significant expansion of its AI offerings within the DigitalOcean AI Ecosystem and the formal introduction of the DigitalOcean AI Partner Program. Unveiled at its Deploy London conference, these initiatives bring together leading technology innovators, systems integrators, venture firms, and AI-native startups to create a comprehensive, flexible, and powerful environment for building the next generation of AI applications.

The DigitalOcean AI Ecosystem allows customers to explore what’s possible on DigitalOcean’s comprehensive agentic cloud, helping AI-natives and digital native enterprises create and deploy AI applications seamlessly and effectively. Users of DigitalOcean GradientTM AI Agentic Cloud products benefit from a full suite of tools for AI development, including efficient AMD and NVIDIA GPUs, access to advanced models from leading companies like OpenAI, DeepSeek, Meta, and Mistral. The Ecosystem also offers integrations with popular AI development and integration frameworks such as LangChain, LiteLLM, and dStack. Teaming up with these companies is crucial to providing the "just right" comprehensive toolset that enables businesses to build and ship AI products faster.

DigitalOcean continues to enhance its Gradient AI Agentic Cloud, with several planned integrations including media models from Fal.ai, enabling users to seamlessly generate voice, image, and video within their AI applications, as well as the ability to leverage Vector Search from MongoDB to create more intelligent applications on one comprehensive platform.

“At the heart of AI's progress are the developers who are turning ideas into reality. The Gradient AI Ecosystem is a powerful force multiplier for them, proving that the future isn't just about silicon—it's about software and the collaborative community built on top of it,” said Anush Elangovan, VP of AI Software at AMD. “By providing high-performance AMD GPUs through DigitalOcean’s Gradient AI Agentic Cloud, we ensure the ecosystem is powered by world-class, open-standard hardware. We're not just providing infrastructure; together we're powering the software and the community that will invent tomorrow's AI.”

The comprehensive feature set of the Gradient AI Agentic Cloud empowers developers and enterprises to build powerful, innovative AI applications, offering choice and flexibility through embedded partner integrations and workflows. The dynamic Gradient AI Ecosystem provides AI startups and digital native enterprises like Telnyx and Scribe the ability to future-proof their solutions with access to cutting-edge technology, services, and guidance from DigitalOcean’s partners, opportunities to expand their AI capabilities, and advance their innovations as the industry continues to evolve.

“Our team is committed to giving developers and digital native enterprises the resources, tools, and community they need to scale," said Wade Wegner, Chief Ecosystem and Growth Officer at DigitalOcean. "The DigitalOcean AI Ecosystem extends that support into AI, offering access to practical use cases, tutorials, partner resources, and shared knowledge to accelerate AI-native application development."

The newly launched DigitalOcean AI Partner Program is a cornerstone of the DigitalOcean AI Ecosystem, creating a powerful growth engine for both partners and customers. The DigitalOcean program is designed specifically with AI development and speed in mind. It exceeds standard industry benefits, offering unique advantages built to help partners thrive, including:

Extensive Developer Marketing Support: Gain access to DigitalOcean’s renowned developer marketing engine, that reaches a global audience of over 3 million developers, through joint activities such as technical content, tutorials, and social content

Community and Event Opportunities: Connect with developers through DigitalOcean’s hundreds of annual community, customer, and partner events, including Hacktoberfest, the celebration of developers and open source that reaches over 90,000 participants annually.

Joint Product Development and Channel to Market: Gain access to invaluable channels to market and accelerate growth with the ability to offer products and services directly to DigitalOcean’s 640k+ customers.

"We're thrilled to deepen our collaboration with DigitalOcean, leveraging the Gradient AI platform for its robust infrastructure and tools that power some of our AI applications," said Gorkem Yurtseven, CTO at Fal.ai. "Joining the DigitalOcean AI Partner Program was an attractive next step, as the program offers great opportunities to reach a broad developer audience. We are particularly excited for our upcoming joint integration, which surfaces our generative media platform directly to Gradient AI Platform builders."

The multi-track program provides tailored benefits for several distinct categories:

AI Startups and Natives: Emerging AI leaders receive credits, high-touch product support, unique co-marketing opportunities, and go-to-market resources to help them scale.

Technology Platforms: Leading infrastructure providers, model builders, and AI developer tools receive deep integration support and co-marketing opportunities.

Systems Integrators: A network of expert consultants and builders receive go-to-market resources, product support, and early access to help customers migrate workloads and build robust AI implementations together with DigitalOcean.

Venture Firms: Investment Firms and Accelerators can design customized programs to support and enable their portfolio companies, empowering the next generation of AI-native startups to build, innovate, and scale on DigitalOcean.

“DigitalOcean’s agility makes it an effective partner for startups in a way that goes beyond infrastructure — their support has amplified our growth," said Anish Agarwal, CEO of Traversal. "The Gradient AI Ecosystem provided a strong foundation for us to successfully build agents for DigitalOcean that perform root cause analysis for production incidents and alerts, reducing MTTR by 38% in just a few months, with 82% of incidents in scope.”

Let’s drive the next wave of AI Innovation together. Join the DigitalOcean AI Partner Program and help us build the DigitalOcean AI Ecosystem.

About DigitalOcean

DigitalOcean is the simplest scalable cloud platform that democratizes cloud and AI for digital native enterprises around the world. Our mission is to simplify cloud computing and AI to allow builders to spend more time creating software that changes the world. More than 640,000 customers trust DigitalOcean to deliver the cloud, AI, and ML infrastructure they need to build and scale their organizations. To learn more about DigitalOcean, visit www.digitalocean.com.

RAS AL KHAIMAH, United Arab Emirates, Oct. 02, 2025 (GLOBE NEWSWIRE) -- WeRide (Nasdaq: WRD), a global leader in autonomous driving technology, today announced the launch of Robotaxi GXR and Robobus pilot operations in partnership with the Ras Al Khaimah Transport Authority (RAKTA).

This represents WeRide's first deployment in Ras Al Khaimah and its expansion into a third emirate in the UAE. The pilot integrates WeRide's autonomous vehicles (AVs) into Ras Al Khaimah's public transport system, laying the foundation for broader commercialization across the country. As the sole partner selected for the emirate's smart mobility strategy, WeRide is also the first and only AV company with active operations in Ras Al Khaimah.

The launch was marked by His Highness Sheikh Saud bin Saqr Al Qasimi, UAE Supreme Council Member and Ruler of Ras Al Khaimah becoming the first passenger to ride the WeRide Robobus on public roads. He was joined by Zhang Yiming, Chinese Ambassador to the UAE, and H.E. Eng. Esmaeel Hasan Alblooshi, Director General of RAKTA — underlining strong China-UAE collaboration in next-generation transport.

From right: H.H. Sheikh Saud bin Saqr Al Qasimi, UAE Supreme Council Member and Ruler of Ras Al Khaimah; and Zhang Yiming, Chinese ambassador to the UAE, riding WeRide's Robobus

Starting today, WeRide's Robobus will operate across nine stops on Al Marjan Island, a fast-growing tourism and lifestyle hub in Ras Al Khaimah. Routes will connect hotels, resorts, and landmarks, including the Mövenpick Resort, Hampton by Hilton, and Pullman Hotel, with plans to extend into Mina Island. In parallel, the Robotaxi GXR will serve the city center of Ras Al Khaimah, expanding autonomous mobility beyond tourism areas into the daily lives of residents.

Commercial operations are scheduled to begin in early 2026 as part of RAKTA's public transport system. Passengers will be able to book Robotaxi rides and track Robobus locations via RAKTA's digital mobility app. Services will start with a safety officer onboard, with fully driverless operations planned for a later phase pending regulatory approval.

This launch marks a key milestone in RAKTA’s Comprehensive Mobility Plan 2030, which aims to integrate multiple transport modes into the existing mobility network while advancing sustainability. As part of this plan, RAKTA is developing a regulatory framework for the autonomous mobility sector in line with international best practices and building local capacity to oversee its implementation.

To strengthen collaboration, WeRide also signed a Memorandum of Understanding (MoU) with RAKTA during the launch ceremony, covering the provision of advanced technical solutions, operational support, and training to ensure the safe and efficient deployment of AVs in Ras Al Khaimah. Signed by H.E. Eng. Esmaeel Hasan Alblooshi, Director General of RAKTA, and Jennifer Li, CFO and Head of International of WeRide, the MoU sets the stage for future commercial operations and the broader integration of WeRide's AVs into the emirate's transport network.

The pilot operations and MoU signing follow His Highness Sheikh Saud’s visit to WeRide’s headquarters in Guangzhou last November.

Often called the "Las Vegas of the Middle East", Ras Al Khaimah is accelerating its tourism push, particularly on Al Marjan Island, which will host the Middle East's first casino. Through its partnership with RAKTA, WeRide is supporting Ras Al Khaimah's vision for autonomous transport by enhancing first- and last-mile connectivity, and assisting in the development of protocols and operational standards for the wider deployment of AVs in the city.

About WeRide
WeRide is a global leader and a first mover in the autonomous driving industry, as well as the first publicly traded Robotaxi company. Our autonomous vehicles have been tested or operated in over 30 cities across 11 countries. We are also the first and only technology company whose products have received autonomous driving permits in seven markets: China, the UAE, Singapore, France, Saudi Arabia, Belgium, and the US. Empowered by the smart, versatile, cost-effective, and highly adaptable WeRide One platform, WeRide provides autonomous driving products and services from L2 to L4, addressing transportation needs in the mobility, logistics, and sanitation industries. WeRide was named to Fortune's 2025 Change the World and 2025 Future 50 lists.

Media Contact
[email protected]

Safe Harbor Statement
This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to,” and similar statements. Statements that are not historical facts, including statements about WeRide’s beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. Further information regarding these and other risks is included in WeRide’s filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release. WeRide does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/09188151-bfb3-43f5-9127-13b92aa46725

Item 1 of 2 FA combination image shows an injection pen of Zepbound, Eli Lilly's weight loss drug, and boxes of Wegovy, made by Novo Nordisk. REUTERS/Hollie Adams/Brendan McDermid/Combination/File Photo

[1/2]FA combination image shows an injection pen of Zepbound, Eli Lilly's weight loss drug, and boxes of Wegovy, made by Novo Nordisk. REUTERS/Hollie Adams/Brendan McDermid/Combination/File Photo Purchase Licensing Rights, opens new tab

SummaryCompaniesMost effective drugs for obesity and its complications are semaglutide, tirzepatide, new European guideline saysCertain GLP-1 drugs are best for specific complicationsThe non-binding guideline emphasizes economic considerations in obesity treatmentOct 2 (Reuters) - Novo Nordisk's

(NOVOb.CO), opens new tab and Eli Lilly's

(LLY.N), opens new tab blockbuster weight-loss drugs should be the first medicines doctors reach for to treat obesity and its complications, a major European medical association advised on Thursday.

Semaglutide, the active ingredient in Novo’s Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be the first choice in almost all cases when substantial weight loss is necessary, according to a new guideline from the European Association for the Study of Obesity published in Nature Medicine.

Sign up here.

When a lesser degree of weight loss is required, other medications can be considered, including liraglutide, an older, less effective drug from the same class, naltrexone–bupropion, and phentermine-topiramate, the guideline says.

The EASO guidelines are non-binding on individual countries.

Semaglutide, tirzepatide, and other drugs from the class known as GLP-1 agonists are completely transforming care of obesity and its complications, coauthor Dr. Andreea Ciudin of Vall d’Hebron University Hospital in Barcelona said in a statement.

Although no treatment algorithm can replace the nuanced clinical judgment necessary for comprehensive patient care, the new guidelines can serve to support therapeutic decision-making in obesity, she said.

SPECIFIC DRUGS FOR SPECIFIC CONDITIONSThe guideline authors analyzed previous clinical trial results, evaluating the impact of medications on weight loss, their safety profile, and their effectiveness in the presence of specific complications.

For patients with the physical consequences of too much fatty, or adipose, tissue, tirzepatide should be considered as the first-line treatment for addressing obstructive sleep apnea, and semaglutide for those with knee osteoarthritis, the authors determined.

For patients with conditions linked with obesity-related metabolic and immune dysfunction, they recommend semaglutide as a first choice for those with a history of heart disease or stroke, tirzepatide for individuals with non-alcoholic fatty liver disease, and either tirzepatide or semaglutide for those with prediabetes or type 2 diabetes.

The class of drugs was originally developed to treat type 2 diabetes.

While the drugs are expensive and economic considerations are complex, the cost of not treating obesity at early stages, “thus enabling the progression to complications and end-organ damage, should be weighed equally in health policy and clinical decision-making,” the guideline authors wrote.

The management of obesity should not be limited to weight loss and its complications but should focus on enhanced mental well-being, physical fitness, social functioning, and overall health and quality of life as well, they also said.

Most of the newer medications have not been evaluated for the treatment of individual complications, they acknowledge.

Still, the authors say, the weight-loss effects have been strongly associated with improvements in various complications and there is growing potential for them to positively influence a broader range of disorders such as chronic kidney disease, neurodegenerative diseases, polycystic ovary syndrome, certain cancers, and mental health conditions.

“Given the rapid advances in the field of medications to treat obesity, EASO intends to update the present treatment algorithm regularly to incorporate the latest available evidence,” society President Professor Volkan Yumuk of Istanbul University-Cerrahpaşa said in a statement.

The American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society jointly advised in June that GLP-1 treatment must be accompanied by nutritional and lifestyle strategies.

“Although GLP‐1s alone can produce significant weight reduction and related health benefits, several challenges limit its long‐term success for individuals and populations,” including gastrointestinal side effects, risk of nutrient inadequacies, muscle and bone loss, high costs, frequent discontinuation, and weight regain,” the advisory said.

Reporting by Nancy Lapid; Editing by Caroline Humer and Bill Berkrot

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Nancy has been a health news reporter and editor at Reuters for more than a decade, covering important medical research advances. She is the author of our twice-a-week Reuters Health Rounds newsletter.

CarMax (NYSE:KMX) shares have dropped by 23% during the past five trading days, reaching approximately $44 per share. Furthermore, the stock is now down over 40% year-to-date.

SINGAPORE--(BUSINESS WIRE)--NielsenIQ (“NIQ”) (NYSE: NIQ), a leader in consumer intelligence, in collaboration with World Data Lab (WDL), today reveal that Generation X is emerging as a trillion-dollar consumer powerhouse in Asia Pacific — and yet, remains under-recognized in marketing strategies across industries.

Often referred to as the “invisible generation,” Gen X (born 1965–1980) wields extraordinary economic influence, especially in multigenerational households common across the region. The global generational spending report, The X Factor: How Generation X is quietly driving trillions in consumer spending, found that Gen X in Asia Pacific is projected to spend an estimated USD 4.4 trillion by end of 2025. The figure is expected to rise to USD 5.7 trillion by 2030, reflecting a steady growth as Gen X continues to support multigenerational households and drive demand across essential and premium categories. This cohort is in its peak earning and spending years, driving growth across consumer packaged goods (CPG) and tech & durables (T&D) categories.

“Marketers have been busy chasing Gen Z and Millennials, but Gen X is the one quietly holding the purse strings,” said Roosevelt D’Souza, Customer Success Leader for Asia Pacific at NIQ. “In many Asian households, they manage the family budget, influence what gets purchased, and take care of both their children and aging parents. That’s a level of influence brands cannot afford to ignore.”

Gen X’s dual role as caregiver and consumer is becoming even more pronounced. NIQ’s latest findings reveal that 27% of Gen X consumers in Asia Pacific expect to spend more time caring for senior relatives over the next 2-5 years—while also supporting their children or extended family. Meanwhile, 43% say that investing in health and wellness has become more important, as they recognize they may only be at the midpoint of their lives.

Strategic Imperative

The next five years represent a once in-a-lifetime window to capture GenX’s loyalty. By 2030, their share of global spending will begin to decline as Millennials take the lead. In China, Millennials are set to overtake Gen X spending by 2027. Brands that act now can secure long-term Gen X consumer behavior, championing brand innovation, and staying attuned to the shifting priorities and expectations of this influential cohort.

“Gen X is not a transitional generation—it’s the region’s present-day profit center,” stated Terence Colle, Managing Director, Strategic Analytics & Insights at NIQ Asia Pacific. “They are pragmatic, digitally fluent, and deeply influential. Our analysis shows that Gen X’s consumer behavior reflects both stability and high expectations. Brands that want to win in Asia Pacific must act now—by decoding Gen X’s decision-making patterns, anticipating their needs, and delivering meaningful innovation. The Gen X decade is underway, and the opportunity to earn their loyalty—and lifetime value—is closing fast.”

What Drives Gen X in APAC

Gen X consumers in Asia Pacific are financially confident, brand-loyal, and pragmatic —making them a key consumer segment across FMCG and Tech & Durables categories. Their shopper journey is marked by a practical approach to research, brand comparison, and multi-channel purchasing — blending in-store familiarity with digital convenience. Their spending is measured and intentional, reflecting the weight of multigenerational caregiving responsibilities. They prioritize trusted brands for daily essentials and selectively upgrade to premium products that offer quality and value, especially for shopping for their families. Health and wellness is a growing focus, with rising demand for vitamins, supplements, and aging-related products. They also embrace technology with a balanced mindset, favoring useful AI tools while maintaining data privacy concerns. Sustainability is a strong purchase driver, with many willing to switch retailers for greener alternatives. This high-intent, values-driven behavior positions Gen X as a commercially active and influential cohort for brands in Asia Pacific.

What Sets APAC Markets Apart

While APAC Gen X shares common consumer behaviors—such as trust in brands, digital fluency, and thoughtful spending—distinct market behaviors present critical opportunities for tailored strategies. Below are country-specific insights revealing what makes each market unique:

Australia

Gen X consumers in Australia acts as the CFO of three generations—driving spend across categories that reflect multigenerational needs, including vitamins, fresh eggs, flavored RTD (ready-to-drink) beverage, cheeses, frozen bakery snacks, energy drinks, frozen pasta meals, dog food, and large mammal foods. Some categories like diet/nutrition and other medicinal products can point to increased investment in self-care.

China

37% of global Gen X born in China; Millennials to overtake by 2027. Fastest-growing categories in China include bicycles & e-bikes, financial services fees, soft drinks, elder & dependent care, and air travel.

India

Gen X is not the dominant spending cohort but it is still significantly spending. Wine and air travel are two of the fastest-growing categories, followed by vehicles, financial services fees, and personal care durables.

Indonesia

Gen X consumers in Indonesia are driving growth in adult powder milk segment, especially through sachet formats that support affordability and trial. Household penetration is increasing with the introduction of sachet packs, signaling growing health consciousness and a shift towards convenient nutrition.

Japan

Projected to spend over USD 728 billion by 2030

Korea

Gen X in Korea is prioritizing aging-related health needs, with significant growth in online sales of joint health and bone health products. Notable trends include rising sales of chondroitin (+49% vs YOY/MAT April 2024) for joint support, as well as MBP (Milk Basic Protein, +10% YoY/MAT April 2024) for bone health. Cognitive enhancement products like phosphatidylserine (+168% YoY/MAT April 2024) are also gaining traction, reflecting Gen X’s growing sophistication and diversification in health choices.

Singapore

Per capita spending projected at USD 27,500 in 2025, rising to USD 33,500 by 2030

Thailand

Expected to spend over USD 80.4 billion by end of 2025, rising to more than USD 94.2 billion by 2030

About The X Factor

The X Factor: How Generation X is quietly driving trillions in consumer spending provides a global analysis of Gen X consumer behavior and spending trends, based on proprietary NIQ and World Data Lab (WDL) data, including WDL’s consumer spending forecasts. This report will show why the next decade represents a once-in-a-lifetime opportunity for brands and retailers to capture Gen X loyalty and lifetime value. Download a free copy of the report.

About NIQ

NielsenIQ (NIQ) is a leading consumer intelligence company, delivering the most complete understanding of consumer buying behavior and revealing new pathways to growth. Our global reach spans over 90 countries covering approximately 85% of the world's population and more than $7.2 trillion in global consumer spend. With a holistic retail read and the most comprehensive consumer insights—delivered with advanced analytics through state-of-the-art platforms—NIQ delivers the Full View™.

For more information, please visit www.niq.com.

About World Data Lab

World Data Lab (WDL) creates forward-looking proprietary data to quantify and forecast consumer trends, consumer spending, demographic shifts, and progress towards the Sustainable Development Goals up to 2034. Our advanced data science approach, which has been peer-reviewed and published in Nature, delivers unrivaled accuracy, freshness, and consistency across all demographic groups in 180 countries and more than 6,000 cities.

For more information or questions, please visit https://worlddatalab.com or contact [email protected]

Forward-Looking Statement

This press release may contain forward-looking statements regarding anticipated consumer behaviors, market trends, and industry developments. These statements reflect current expectations and projections based on available data, historical patterns, and various assumptions. Words such as “expects,” “anticipates,” “projects,” “believes,” “forecasts,” and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future outcomes and are subject to inherent uncertainties, including changes in consumer preferences, economic conditions, technological advancements, and competitive dynamics. Actual results may differ materially from those expressed or implied in these statements. While we strive to base our insights on reliable data and sound methodologies, we undertake no obligation to update any forward-looking statements to reflect future events or circumstances, except to the extent required by applicable law.

© 2025 Nielsen Consumer LLC. All Rights Reserved.

Wall Street projects third-quarter global EV delivery volumes of about 443,000 vehicles, down from about 463,000 delivered in the third quarter of 2024.

FORNEBU, Norway, Oct. 2, 2025 /PRNewswire/ -- Reference is made to the extraordinary general meeting of Aker Carbon Capture ASA (under liquidation) (the "Company") held on 5 August 2025 where the general meeting resolved to liquidate the Company and the announcement made by the Company on 1 October 2025 regarding an updated liquidation settlement and liquidation dividend. Key information relating to the updated liquidation dividend is set out below, where the record date has now been corrected: Dividend amount: NOK 0.137 per share Declared currency: NOK Last day including right: 10 October 2025 Ex-date: 13 October 2025 Record date: 14 October 2025 Payment date: On or about 17 October 2025 Date of approval: 1 October 2025 For further information:Media and Investors: Mats Ektvedt Mobile: 41423328E-mail: [email protected] This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act and Euronext Oslo Rule Book II.

Whales buy 250M XRP in 48 hours. Price nears ATH as ETF talk grows and key chart patterns suggest a possible breakout is coming.

Large holders of XRP have moved quickly, adding 250 million tokens to their wallets within 48 hours. This comes as price levels and market activity show early signs of a possible shift.

Analysts and traders are monitoring key metrics, including whale behavior, exchange flows, and technical resistance zones.

Whale Wallets Increase Holdings Rapidly
According to market analyst Ali Martinez, wallets holding between 100 million and 1 billion XRP accumulated 250 million tokens over a two-day period. This is a sharp rise after several weeks of flat activity among large holders. The change points to renewed movement from a group often linked with strategic positioning.

250 million $XRP bought by whales in 48 hours! pic.twitter.com/S0DZYQms7i

— Ali (@ali_charts) October 1, 2025

During this same period, the price of XRP moved from about $2.87 to $2.94. While this increase is modest, similar buying behavior in the past has often led to further price movement. Whether that trend continues is now a key focus for traders.

Meanwhile, data from CryptoQuant shows that XRP reserves on Binance rose sharply in late September. The total increased from around 3.1 billion to 3.5 billion XRP in a single day. It is the largest rise in reserves seen this year.

Source: CryptoQuant
Between January and August, XRP balances on Binance mostly declined as the asset’s price moved higher. The recent inflow may point to added liquidity for trading, internal shifts by the exchange, or possible preparation for selling. For now, XRP remains steady at close to $3.00.

You may also like:

Ripple CTO Steps Down – How Will This Big Leadership Change Affect XRP?

Ripple (XRP) Breakout Delayed? Bearish Signals Suggest Further Downside Testing

$1 Billion Liquidation Storm Hits as BTC, ETH, XRP Collapse

Price Nears Long-Term Resistance
XRP is currently trading near a major resistance level formed by its previous all-time high. Based on a multi-phase chart pattern shared by CW, the current market phase has historically aligned with strong upward price movement. The asset remains just below the key breakout zone.

Targets above this level include $6.61 and $21.5, based on technical projections. Market attention is also on reports that an XRP ETF may be approved by mid-month. CW noted,

“The real rally for $XRP is starting. It just needs to break above its ATH line.”

Source: CW/X
XRP vs Bitcoin Chart Builds Pressure
The XRP/BTC chart shows a W-pattern forming over the past six years. The 0.000027 BTC level remains the main resistance. According to CryptoWZRD, a breakout above that line would confirm a reversal and may trigger stronger performance for XRP against Bitcoin.

🔮 GAME STILL TO COME 🤩

What if I told you, the real move is still to come..

⚠️ For nearly 6 years $XRP against $BTC has been trading below 0.00002700, but the W-Pattern is ready 🚀

Once it breaks it will trigger a parabolic rally above $3.65 to new highs 😇 pic.twitter.com/kcLVjrYCtM

— CRYPTOWZRD (@cryptoWZRD_) October 1, 2025

In a separate update, the analyst reported a strong daily close for XRP, but noted that a move from XRP/BTC still depends on a drop in Bitcoin Dominance. Support is marked at $2.75, while a push above $3.15 could open the way to $3.65 or higher.

Tags:

Canaan has signed a colocation agreement with Soluna to host 1 EH/s of its Avalon 15XP bitcoin miners as the manufacturer seeks to turn inventory surplus into proprietary mining expansion in North America.